Medifast, Inc.
MED
$10.53
$0.100.96%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -36.90% | -36.21% | -37.38% | -33.77% | -37.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -36.90% | -36.21% | -37.38% | -33.77% | -37.70% |
| Cost of Revenue | -25.43% | -20.99% | -35.92% | -33.65% | -37.99% |
| Gross Profit | -40.90% | -41.18% | -37.91% | -33.82% | -37.60% |
| SG&A Expenses | -20.03% | -36.43% | -41.17% | -28.60% | -43.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.64% | -32.28% | -39.57% | -29.86% | -41.98% |
| Operating Income | -159.06% | -293.78% | 86.47% | -115.89% | 52.27% |
| Income Before Tax | -600.55% | -268.38% | 127.00% | -95.46% | -86.99% |
| Income Tax Expenses | 2,376.16% | -188.20% | 115.83% | -60.29% | -87.42% |
| Earnings from Continuing Operations | -2,362.05% | -300.27% | 130.41% | -109.28% | -86.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,362.05% | -300.27% | 130.41% | -109.28% | -86.73% |
| EBIT | -159.06% | -293.78% | 86.47% | -115.89% | 52.27% |
| EBITDA | -126.46% | -111.87% | 161.95% | -81.98% | 36.30% |
| EPS Basic | -2,352.05% | -299.32% | 130.26% | -109.25% | -86.79% |
| Normalized Basic EPS | -146.10% | -267.52% | 126.86% | -95.48% | 39.97% |
| EPS Diluted | -2,458.37% | -310.00% | 129.33% | -109.28% | -87.20% |
| Normalized Diluted EPS | -146.29% | -268.08% | 126.70% | -95.46% | 39.95% |
| Average Basic Shares Outstanding | 0.48% | 0.49% | 0.49% | 0.36% | 0.41% |
| Average Diluted Shares Outstanding | 0.07% | 0.18% | 1.12% | -0.09% | 0.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -1.00% | 1.82% | -3.94% | -1.00% |